Hydreight Highlights U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Technology

Hydreight's Insu investment advances with a U.S. patent allowance, but commercialization remains distant.

What the company is saying

Hydreight Technologies Inc. highlights that Insu Therapeutics, in which it holds a strategic stake, has received a Notice of Allowance from the USPTO for a patent application covering buccal peptide-delivery technology. The announcement emphasizes the strengthening of Hydreight's intellectual property position and potential U.S. distribution rights for future peptide medicines using Insu's platform. The company frames this as a milestone for its investment and underscores the opportunity to connect innovative drug delivery with its established U.S. healthcare infrastructure. CEO Shane Madden is quoted on the strategic fit and future distribution potential, while Dr. Anubhav Pratap-Singh, Insu's Board chair and Co-Founder, stresses the combination of exclusive technology rights and formulation research. The tone is confident but acknowledges that InsuTab and BuccaGLP are still investigational, with no regulatory approvals or commercial sales. The company is clear that further development, regulatory clearance, and operational arrangements are prerequisites for any commercial rollout.

What the data suggests

The only direct financial figure is Hydreight's C$300,000 investment in Insu, previously disclosed. Hydreight's operational scale is quantified as a network of over 3,000 nurses and more than 300 independent doctors and pharmacy relationships across all 50 U.S. states. The patent milestone is real: Insu received a Notice of Allowance for U.S. Patent Application No. 18/513,373, covering a mucoadhesive, unidirectional peptide-delivery platform. Insu holds an exclusive, worldwide license from the University of British Columbia for this technology, with related patent applications in the United States, Canada, Europe, and Japan. InsuTab and BuccaGLP remain preclinical, supported by laboratory, cell-culture, and rat studies at UBC; no human data or regulatory submissions are disclosed. Hydreight's U.S. distribution rights are in place but contingent on Insu's candidates completing development and receiving approvals. The announcement is transparent about the early stage of the products and the conditional nature of future commercial opportunities.

Analysis

The announcement is upbeat, highlighting a Notice of Allowance for a U.S. patent application and Hydreight's strategic investment in Insu Therapeutics. The realised facts are the patent milestone, the C$300,000 investment, and the operational scale of Hydreight's platform. However, the commercialisation of Insu's buccal peptide-delivery technology is still distant: both InsuTab and BuccaGLP remain investigational, with only preclinical (lab, cell, rat) studies completed and no human data or regulatory submissions disclosed. The release repeatedly references potential future distribution and commercial opportunities, but these are explicitly contingent on successful further development and regulatory approvals. The tone is optimistic, but the gap between narrative and evidence is moderate: the patent milestone is real, but the path to revenue or product launch is long-term and uncertain. No large new capital outlay is disclosed in this release, and the investment amount is modest.

Risk flags

• ●Commercialization risk is high because InsuTab and BuccaGLP are still investigational, with no human clinical data or regulatory submissions disclosed; the path to market is uncertain and could face scientific or regulatory setbacks.
• ●Hydreight's U.S. distribution rights, while secured, offer no guaranteed revenue or timeline, as they are entirely dependent on Insu's ability to achieve successful development and obtain regulatory approvals.
• ●The patent's ultimate scope of protection is not yet finalized, as the allowed claims are subject to the final issued claims; this could affect the breadth of intellectual property protection and competitive advantage.
• ●There is no disclosure of additional funding, clinical trial plans, or partnerships to support Insu's further development, raising questions about the pace and resourcing of future progress.

Bottom line

Hydreight's C$300,000 investment in Insu Therapeutics has gained some validation with the U.S. patent allowance for a novel buccal peptide-delivery technology, but this is an early-stage milestone. The products in question, InsuTab and BuccaGLP, are still in preclinical development, with only laboratory and animal data available and no regulatory submissions underway. Hydreight's U.S. distribution rights could become valuable, but only if Insu's candidates successfully navigate clinical trials and regulatory hurdles—a process likely to take years. The company's operational scale in the U.S. healthcare market is real, but there is no immediate path to revenue from this technology. Investors should recognize this as a long-term, high-risk, high-reward proposition, with the most important takeaway being that value realization is entirely contingent on future clinical and regulatory success.

Announcement summary

(TSXV:NURS) (OTCQB:HYDTF) (FSE:SO6) (CSE:VST) (OTC:VSQTF) Hydreight Technologies Inc. announced that Insu Therapeutics Inc., in which Hydreight holds a strategic investment, has received a Notice of Allowance from the United States Patent and Trademark Office for a patent application covering its buccal peptide-delivery technology. The patent application, U.S. Patent Application No. 18/513,373, is titled 'Mucoadhesive Pharmaceutical Dosage Form for Unidirectional Release of Peptide Therapeutic Particles.' Hydreight completed a C$300,000 investment in Insu and obtained U.S. distribution rights for peptide medicines incorporating Insu's buccal technology, as disclosed in its March 13, 2026 news release. Insu holds an exclusive, worldwide licence from the University of British Columbia to develop, market, commercialize, and sublicense the licensed technology globally. The allowed claims relate to the platform's mucoadhesive, layered dosage-form architecture and unidirectional release mechanism for insulin and GLP-1 therapeutics, including semaglutide, liraglutide, dulaglutide, exenatide, and multiple insulin analogues. InsuTab™ and BuccaGLP™ are Insu's investigational buccal insulin and semaglutide formulations, respectively, and both remain investigational and are not approved for commercial sale. Insu has completed laboratory, cell-culture, and rat studies at UBC as proof-of-concept work for its buccal insulin program. Hydreight's platform connects healthcare providers, pharmacies, and patients across all 50 U.S. states and supports a network of more than 3,000 nurses and more than 300 independent doctors and pharmacy relationships. Hydreight's VSDHOne platform, developed in partnership with Victory Square Technologies (CSE:VST, OTC:VSQTF, FSE:6F6), supports businesses delivering physician-supervised healthcare through virtual and direct-to-consumer channels. Insu's technology is designed to deliver peptide medicines through the lining of the mouth, providing a potential needle-free alternative to injections, and does not require fasting or restrictions on food and drink before or after dosing. The patent allowance strengthens Hydreight's strategic investment and potential future U.S. distribution opportunity, but any future introduction would require successful development, regulatory approvals, and appropriate product-specific prescribing, pharmacy, and operational arrangements. The scope of patent protection will be determined by the final issued claims. Insu's research was published in Pharmaceutics in September 2023 (15(9):2265). Shane Madden is the Chief Executive Officer and Director of Hydreight Technologies Inc. Dr. Anubhav Pratap-Singh is Board chair and Co-Founder of Insu Therapeutics. Insu holds related patent applications in the United States, Canada, Europe, and Japan.

Disagree with this article?